UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MEDTRONIC, INC. Petitioner

v.

NUVASIVE, INC. Patent Owner

Case IPR2013-00507 U.S. Patent No. 8,187,334 B2

Before SALLY C. MEDLEY, LORA M. GREEN, and STEPHEN C. SIU, *Administrative Patent Judges*.

SIU, Administrative Patent Judge.

DECISION Institution of *Inter Partes* Review 37 C.F.R. § 42.108



Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

I. BACKGROUND

A. Background

Medtronic, Inc. ("Petitioner") filed a petition requesting an *inter partes* review of claims 1-5, 10, 11, and 14-28 of U.S. Patent No. 8,187,334 B2 ("the '334 patent," Ex. 1013) pursuant to 35 U.S.C. §§ 311-319. Paper 1 ("Pet."). NuVasive, Inc. ("Patent Owner") filed a preliminary response ("Prelim. Resp."). Paper 6. We have jurisdiction under 35 U.S.C. § 314. The standard for instituting an *inter partes* review is set forth in 35 U.S.C. § 314(a), which provides:

THRESHOLD – The Director may not authorize an inter partes review to be instituted unless the Director determines that the information presented in the petition filed under section 311 and any response filed under section 313 shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.

We determine based on the record that Petitioner has shown, under 35 U.S.C. § 314(a), that there is a reasonable likelihood that it would prevail with respect to at least one of the challenged claims.

Petitioner relies on the following prior art:

US 2002/0165550 A1 (Frey)	Nov. 7, 2002	Ex. 1003
US 2003/0028249 A1 (Baccelli)	Feb. 6, 2003	Ex. 1004
US 5,860,973 (Michelson)	Jan. 19, 1999	Ex. 1005
US 2003/0100950 A1 (Moret)	May 29, 2003	Ex. 1006
US 2003/0139813 A1 (Messerli)	Jul. 24, 2003	Ex. 1007

Petitioner contends that the challenged claims are unpatentable under 35 U.S.C § 103(a) based on the following specific grounds (Pet. 3):

Reference(s)	Basis	Claims challenged
Frey	§ 102(b)	1-3, 10, 14, 15, and 19-28
Frey and Baccelli	§ 103(a)	1-5, 10, 11, 14-17, and 19- 28
Frey and Messerli	§ 103(a)	1-3, 10, 14, 15, and 19-28
Frey and Michelson	§ 103(a)	1-5, 10, 11, 14, 15, and 18- 28
Frey and Moret	§ 103(a)	1-3, 10, 14, 15, and 19-28

B. The '334 patent

The '334 patent describes a spinal fusion system, including a spinal fusion implant and an insertion instrument. Ex. 1013, col. 5, ll. 6-9. The spinal fusion implant is introduced into the disc space via a lateral approach to the spine or via a posterior, anterior, antero-lateral, or postero-lateral approach, and is made from a radiolucent material, such as PEEK (poly-ether-ether-ketone). *Id.* at col. 5, ll. 10-15 and 29-33. In one embodiment, the spinal fusion implant has a width ranging between 9 and 18 mm and a length ranging between 25 and 44 mm. *Id.* at col. 5, ll. 17-19.

Claim 1 of the '334 patent is reproduced below:

1. A spinal fusion implant of non-bone construction positionable within an interbody space between a first vertebra and a second vertebra, said implant comprising:

an upper surface including anti-migration elements to contact said first vertebra when said implant is positioned within the interbody space, a lower surface including anti-migration elements to contact said second vertebra when said implant is positioned within the interbody space, a distal wall, a proximal wall, a first sidewall and a second sidewall, said distal wall, proximal wall, first sidewall, and second sidewall comprising a radiolucent material; wherein said implant has a longitudinal length greater than 40 mm extending from a proximal end of said proximal wall to a distal end of said distal wall;

wherein a central region of said implant includes portions of the first and second sidewalls positioned generally centrally between the proximal wall and the distal wall, at least a portion of the central region defining a maximum lateral width of said implant extending from said first sidewall to said second sidewall, wherein said longitudinal length is at least two and halftimes greater than said maximum lateral width;

at least a first fusion aperture extending through said upper surface and lower surface and configured to permit bone growth between the first vertebra and the second vertebra when said implant is positioned within the interbody space, said first fusion aperture having: a longitudinal aperture length extending generally parallel to the longitudinal length of said implant, and a lateral aperture width extending between said first sidewall to said second sidewall, wherein the longitudinal aperture length is greater than the lateral aperture width; and

at least three radiopaque markers; wherein a first of the at least three radiopaque markers is at least partially positioned in said distal wall, a second of said at least three radiopaque markers is at least partially positioned in said proximal wall, and a third of said at least three radiopaque markers is at least partially positioned in said central region.

According to Petitioner, the '334 patent is the subject of co-pending district court litigation, *Warsaw Orthopedic, Inc. v. NuVasive, Inc.*, originally filed in the Northern District of Indiana, Case No. 3:12-cv-00438-JD-CAN, on August 17, 2012, and transferred to the Southern District of California on November 8, 2012, as Case No. 3:12-cv-02738-CAB-MDD. *See* Pet. 1. Petitioner has filed a second petition seeking *inter partes* review of the '334 patent (IPR2013-00508) and two additional petitions seeking *inter partes* review of related U.S. Patent No. 8,361,156 B2 (IPR2013-00504 and IPR2013-00506).

C. Claim Interpretation

Consistent with the statute and the legislative history of the Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 329 (2011) ("AIA"), the Patent Trial and Appeal Board ("Board") interprets claim terms by applying the broadest reasonable construction in the context of the Specification in which the claims reside. 37 C.F.R. § 42.100(b); *see* Office Patent Trial Practice Guide, 77 Fed. Reg. 48,756, 48,766 (Aug. 14, 2012.)

Under the broadest reasonable interpretation standard, claim terms are given their ordinary and customary meaning, as would be understood by one of ordinary skill in the art in the context of the entire disclosure. *In re Translogic Tech., Inc.*, 504 F.3d 1249, 1257 (Fed. Cir. 2007). Any special definition for a claim term must be set forth in the specification with reasonable clarity, deliberateness, and precision. *In re Paulsen*, 30 F.3d 1475, 1480 (Fed. Cir. 1994). In this regard, however, we are careful not to read a particular embodiment appearing in the written description into the claim if the claim language is broader than the embodiment. *In re Van Geuns*, 988 F.2d 1181, 1184 (Fed. Cir. 1993).

Petitioner provides a construction for each of "distal wall / proximal wall" (claim 1), "releasably mate" (claim 3), "longitudinal length" (claim 11), "extend generally perpendicular to said longitudinal length" (claim 11), "elongate body" (claims 14 and 17), "generally rectangular and generally oblong in shape" (claim 23), "lateral width of the distal end of said distal wall / a lateral width of said proximal end of said proximal wall" (claim 24), and "oriented generally parallel to a height of the implant" (claim 17 recites an elongate body oriented generally perpendicular to said longitudinal length and entirely through a height of said

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.